GSK has secured accelerated approval from the FDA for neladalkib in ALK-positive non-small cell lung cancer, giving the company its second regulatory win from the $10.6 billion Nuvalent Bio acquisition it completed in June. The drug will be sold as Nelkarmi.
The label covers patients with advanced disease who have received prior lines of treatment for unresectable tumors. Because the decision came through the accelerated pathway, GSK must verify clinical benefit in a confirmatory study to keep the approval.
The data
The approval was supported by the Phase 1/2 ALKOVE-1 study, which enrolled 700 patients with ALK-positive solid tumors. GSK said one of the trial’s primary outcomes is objective response rate.
In patients whose only prior exposure to ALK-targeted tyrosine kinase inhibitors was Genentech’s Alecensa, Nelkarmi posted a 49% objective response rate. In patients who had received at least two prior lines of ALK TKI therapy, objective response rate was 32%.
GSK also emphasized the drug’s activity in disease that has spread to the brain. In ALKOVE-1, intracranial objective response rate reached 55% in patients with measurable metastasis in the central nervous system whose only prior ALK TKI was Alecensa. That positioning matters in ALK-positive NSCLC, where resistance and central nervous system progression remain major treatment problems after earlier TKIs.
On safety, GSK said 5% of treated patients permanently discontinued Nelkarmi because of adverse reactions, most commonly liver toxicities. The prescribing information carries warnings and precautions for hepatotoxicity, renal toxicity, ocular toxicity, creatine phosphokinase elevation and embryo-fetal toxicity. Common side effects include constipation, muscle or bone pain, edema and fatigue.
The commercial picture
Nelkarmi follows zidesamtinib, approved in July as Jideytro, as the second marketed NSCLC asset from Nuvalent. That sequence gives GSK a clearer near-term payoff from one of the industry’s largest deals this year rather than a longer wait for pipeline maturation. Nuvalent also brought GSK the Phase 1 HER2 blocker NVL-330 for NSCLC.
GSK said Nelkarmi had previously received breakthrough therapy designation. The company is also running the Phase 3 ALKAZAR study in TKI-naive ALK-positive NSCLC patients and other solid tumors, which now becomes the key program for expanding the asset beyond its current post-treatment setting.




